DePuy Orthopaedics Newswire

Comprehensive Real-Time News Feed for DePuy Orthopaedics.

Results 1 - 20 of 602 in DePuy Orthopaedics

  1. One Put, One Call Option To Know About for Johnson & JohnsonRead the original story w/Photo

    22 hrs ago | Forbes.com

    Consistently, one of the more popular stocks people enter into their stock options watchlist at Stock Options Channel is Johnson & Johnson . So this week we highlight one interesting put contract, and one interesting call contract, from the April 2015 expiration for JNJ.

    Comment?

  2. Baron and Budd Investigating Hip Replacement LawsuitsRead the original story

    23 hrs ago | Business Wire

    ... Baron and Budd. Manufacturers of the hip replacement implants under investigation include Wright Medical, DePuy Orthopaedics (a subsidiary of Johnson & Johnson), Smith and Nephew, Stryker, Zimmer and Biomet. In many instances, patients receiving ...

    Comment?

  3. Want to claw your way to the top? A new book shows you howRead the original story w/Photo

    Friday Oct 17 | New York Post

    A new book, "The Social Climber's Bible," offers a set of guidelines for climbing one's way to the top. You could slave away for years in hopes of one day landing a corner office - or you could simply charm, brown-nose and flatter your way up the career ladder.

    Comment?

  4. Recent Purchase: Johnson & JohnsonRead the original story w/Photo

    Friday Oct 17 | Seeking Alpha

    Johnson & Johnson posted operating results for the third quarter that mildly exceeded my expectations, with strong sales in its Pharmaceuticals offsetting sales declines in Consumer Products and Medical Devices. Though sales of Olysio will probably not continue to grow as robustly as they did this quarter, I am optimistic about the prospects for Xarelto, Invokana, and Imbruvica.

    Comment?

  5. Cancer vaccine maker inks deal up to $817 million with Johnson & JohnsonRead the original story w/Photo

    Thursday Oct 16 | Seattle Post-Intelligencer

    Aduro BioTech in Berkeley has struck another big development deal with Johnson & Johnson, this time to work on its lung cancer vaccine in a partnership worth up to $817 million, the companies said Thursday. The deal is Aduro's second with Janssen Biotech, Johnson & Johnson's pharmaceutical arm, following a May agreement to develop a prostate cancer vaccine for up to $365 million.

    Comment?

  6. Arthur L. Johnson students attend knee replacement surgery through...Read the original story w/Photo

    Thursday Oct 16 | The Jersey Journal

    Arthur L. Johnson students selected from Bernadette Jacobi's Predmedical Studies Class, AP Biology class, and Anatomy & Physiology A class attend a Knee Replacement Surgery through Liberty Science Center's 'Live From Surgery' Program. On Oct. 7, students from Arthur L. Johnson High school were privileged to attend a knee replacement surgery through the Liberty Science Center's "Live From Surgery" Program.

    Comment?

  7. Cancer vaccine maker inks deal up to $817 million with Johnson &...Read the original story w/Photo

    Thursday Oct 16 | SFGate

    Aduro BioTech in Berkeley has struck another big development deal with Johnson & Johnson, this time to work on its lung cancer vaccine in a partnership worth up to $817 million, the companies said Thursday. The deal is Aduro's second with Janssen Biotech, Johnson & Johnson's pharmaceutical arm, following a May agreement to develop a prostate cancer vaccine for up to $365 million.

    Comment?

  8. Pinnacle Hip Help Website by Kershaw|Talley LLP Offers Guidance as...Read the original story w/Photo

    Wednesday Oct 15 | PRWeb

    ... evaluation form or call (888) 522-2372 for a free confidential case review. *The case is Herlihy-Paoli v. DePuy Orthopaedics Inc., 12- cv-3590, U.S. District Court, Northern District of Texas (Dallas).

    Comment?

  9. Johnson & Johnson Earnings: Showing Surprising WeaknessRead the original story

    Wednesday Oct 15 | The Motley Fool

    But looking under the surface, things didn't appear nearly as positive. And in the video below, Motley Fool health care analyst Michael Douglass lays out his concerns with Johnson & Johnson and what he thinks about this top dividend stock.

    Comment?

  10. Why Johnson & Johnson (JNJ) Stock Is Up TodayRead the original story w/Photo

    Wednesday Oct 15 | TheStreet.com

    Third quarter sales were $18.5 billion compared to $17.6 billion for the same quarter in 2013, the company said. J&J, which makes a range of health-care products, including prescription drugs and medical devices, is considered a bellwether for the industry because its portfolio touches so many sectors.

    Comment?

  11. Dow Movers: HD, JNJRead the original story w/Photo

    Wednesday Oct 15 | Forbes.com

    Our mission at Market News Video is to produce and distribute quality online videos about the stock markets and publicly traded companies. We achieve our mission by delivering videos to visitors to our MarketNewsVideo.com website and through our distribution partners.

    Comment?

  12. Johnson & Johnson and Bristol-Myers Squibb's New Collaboration Just the Tip of the IcebergRead the original story

    Wednesday Oct 15 | The Motley Fool

    The companies didn't disclose the terms of the collaboration except to say Johnson & Johnson would run the initial studies. ) , is already approved in the U.S. to treat mantle cell lymphoma and chronic lymphocytic leukemia.

    Comment?

  13. Wright & Schulte LLC Continues To File DePuy Pinnacle Hip Lawsuits...Read the original story w/Photo

    Wednesday Oct 15 | PRWeb

    ... side-effects including revision surgeries, chronic pain and metallosis or blood poisoning. (In Re: DePuy Orthopaedics, Inc., Pinnacle Hip Implant Products Liability Litigation, MDL No. 2244) The attorneys at Wright & Schulte LLC are representing ...

    Comment?

  14. Stocks End Mostly Higher as Earning Seasons Kicks OffRead the original story

    Tuesday Oct 14 | Morningstar

    JPMorgan were down around 0.3% after the firm reported third-quarter earnings . Non-interest expenses totaled $15.8 billion, up from $15.4 billion in the second quarter and $14.6 billion in the first.

    Comment?

  15. Johnson & Johnson s products.Read the original story w/Photo

    Tuesday Oct 14 | Philly.com

    Johnson & Johnson lifted its 2014 earnings forecast a third time after pharmaceutical sales helped the world's biggest maker of health care products trump analyst expectations for its recently concluded quarter. J&J booked an 18 percent jump in worldwide pharmaceutical sales in the third quarter, which helped it counter revenue declines in both its medical device and consumer segments.

    Comment?

  16. Johnson & Johnson Given "Neutral" Rating at ZacksRead the original story

    Tuesday Oct 14 | AmericanBankingNews.com

    's stock had its "neutral" rating reissued by Zacks in a research report issued to clients and investors on Tuesday. They currently have a $104.00 price objective on the stock.

    Comment?

  17. Stocks Rise as Earning Seasons Kicks OffRead the original story

    Tuesday Oct 14 | Morningstar

    JPMorgan were down around 1% after the firm reported third-quarter earnings . Non-interest expenses totaled $15.8 billion, up from $15.4 billion in the second quarter and $14.6 billion in the first.

    Comment?

  18. Johnson & Johnson Raises Forecast AgainRead the original story

    Tuesday Oct 14 | Hispanic Business

    Johnson & Johnson lifted its 2014 earnings forecast a third time after pharmaceutical sales helped the world's biggest maker of health care products trump analyst expectations for its recently concluded quarter. J&J booked an 18 percent jump in worldwide pharmaceutical sales in the third quarter, which helped it counter revenue declines in both its medical device and consumer segments.

    Comment?

  19. Johnson & Johnson hikes 2014 forecast a third time after topping quarter ...Read the original story w/Photo

    Tuesday Oct 14 | Nanaimo Daily News

    Johnson & Johnson lifted its 2014 earnings forecast a third time after pharmaceutical sales helped the world's biggest maker of health care products trump analyst expectations for its recently concluded quarter. J&J booked an 18 per cent jump in worldwide pharmaceutical sales in the third quarter, which helped it counter revenue declines in both its medical device and consumer segments.

    Comment?

  20. Morning Movers: Johnson & Johnson, Citigroup Jumps on Earnings Beats; JPMorgan Drops on MissRead the original story w/Photo

    Tuesday Oct 14 | Barron's

    S&P 500 futures have gained 0.7%, while Dow Jones Industrial Average futures have risen 0.5%. Nasdaq Composite futures have advanced 0.8%.

    Comment?